Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10390 in healthy subjects
NCT05942625Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) comparing HS-10390 with Placebo (2 arms). Primary endpoint: Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation. Started May 2023; status: recruiting.
02
Drugs
HS-10390
03
Conditions
IgA nephropathy (IgAN)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05942625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942625.